BEIJING, Dec. 22, 2017 /PRNewswire/ -- Sinovac Biotech
Ltd. (Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider
of biopharmaceutical products in China, announced today that it has received a
positive decision from the World Health Organization ("WHO") on the
acceptability, in principle, of its Healive, a hepatitis A vaccine
product, for purchase by United Nations ("UN") agencies. The
Company's Healive product was assessed according to the WHO
Prequalification Procedure.
Mr. Weidong Yin, Chairman,
President and CEO of the Company, commented that "I am very pleased
that Healive has passed the assessment under WHO Prequalification
procedures. This is an important milestone for Sinovac which we
expect will provide opportunities to supply this vaccine to
respective UN agencies as well as accelerate the regulatory
approval process for this vaccine in international countries
outside China."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu), and
mumps. The EV71 vaccine, an innovative vaccine developed by Sinovac
against hand foot and mouth disease caused by EV71, was
commercialized in China in 2016.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. The
Company is developing a number of new products including a
Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and
varicella vaccine. Sinovac primarily sells its vaccines in
China, while also exploring growth
opportunities in international markets. The Company has exported
select vaccines to over 10 countries in Asia and South America. For more
information, please visit the Company's website
atwww.sinovac.com.
Safe Harbor Statement
This announcement may include certain statements that are not
descriptions of historical facts, but are forward-looking
statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as "will," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates" and similar statements.
Forward-looking statements involve risks, uncertainties and other
factors that could cause actual results to differ materially from
those contained in any such statements.
Contact
Sinovac Biotech Ltd.
Helen
Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/sinovac-biotech-receives-positive-decision-on-its-hepatitis-a-vaccine-from-world-health-organization-300575044.html
SOURCE Sinovac Biotech Ltd.